<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="6934"><DrugName>edodekin alfa</DrugName><DrugNamesKey><Name id="42758269">edodekin alfa</Name></DrugNamesKey><DrugSynonyms><Name><Value>Ro-24-7472/000</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>edodekin alfa</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>Interleukin 12 (human)</Value></Name><Name><Value>IL-12 (human)</Value></Name><Name><Value>YM-01C</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>IL-12, Roche</Value></Name><Name><Value>IL-12, Yamanouchi</Value></Name><Name><Value>interleukin-12, Roche</Value></Name><Name><Value>NKSF, Genetics Institute</Value></Name><Name><Value>rhIL-12, Genetics Institute</Value></Name><Name><Value>interleukin-12, Genetics Institute</Value></Name></DrugSynonyms><CompanyOriginator id="20511">Wyeth BioPharma</CompanyOriginator><CompaniesSecondary><Company id="14199">Wyeth Pharmaceuticals</Company><Company id="19447">Nippon Roche KK</Company><Company id="19461">Hoffmann-La Roche Inc</Company><Company id="20511">Wyeth BioPharma</Company><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="6934" type="Drug"><TargetEntity id="164387" type="siDrug">Edodekin alfa</TargetEntity></SourceEntity><SourceEntity id="14199" type="Company"><TargetEntity id="5000374382" type="organizationId">Wyeth Pharmaceuticals LLC</TargetEntity></SourceEntity><SourceEntity id="19447" type="Company"><TargetEntity id="4296408012" type="organizationId">Nippon Roche KK</TargetEntity></SourceEntity><SourceEntity id="19461" type="Company"><TargetEntity id="4296828058" type="organizationId">Hoffmann-La Roche Inc</TargetEntity></SourceEntity><SourceEntity id="20511" type="Company"><TargetEntity id="5035523512" type="organizationId">Wyeth Biopharma</TargetEntity></SourceEntity><SourceEntity id="153" type="ciIndication"><TargetEntity id="10019744" type="MEDDRA"></TargetEntity><TargetEntity id="D019698" type="MeSH"></TargetEntity><TargetEntity id="-776640207" type="omicsDisease"></TargetEntity><TargetEntity id="430" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="158" type="ciIndication"><TargetEntity id="B20" type="ICD10"></TargetEntity><TargetEntity id="042" type="ICD9"></TargetEntity><TargetEntity id="10020161" type="MEDDRA"></TargetEntity><TargetEntity id="D015658" type="MeSH"></TargetEntity><TargetEntity id="-841965209" type="omicsDisease"></TargetEntity><TargetEntity id="862" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1754" type="ciIndication"><TargetEntity id="D016410" type="MeSH"></TargetEntity><TargetEntity id="836" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1766" type="ciIndication"><TargetEntity id="10067946" type="MEDDRA"></TargetEntity><TargetEntity id="D002292" type="MeSH"></TargetEntity><TargetEntity id="-994324469" type="omicsDisease"></TargetEntity><TargetEntity id="609" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="197" type="ciIndication"><TargetEntity id="D016773" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="205" type="ciIndication"><TargetEntity id="C43" type="ICD10"></TargetEntity><TargetEntity id="10025650" type="MEDDRA"></TargetEntity><TargetEntity id="D008545" type="MeSH"></TargetEntity><TargetEntity id="-361092282" type="omicsDisease"></TargetEntity><TargetEntity id="705" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="221" type="ciIndication"><TargetEntity id="A15" type="ICD10"></TargetEntity><TargetEntity id="10044755" type="MEDDRA"></TargetEntity><TargetEntity id="D014376" type="MeSH"></TargetEntity><TargetEntity id="3389" type="ORPHANET"></TargetEntity><TargetEntity id="-1043612885" type="omicsDisease"></TargetEntity><TargetEntity id="843" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="268" type="ciIndication"><TargetEntity id="10025487" type="MEDDRA"></TargetEntity><TargetEntity id="673" type="ORPHANET"></TargetEntity><TargetEntity id="-2144313480" type="omicsDisease"></TargetEntity><TargetEntity id="850" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="298" type="ciIndication"><TargetEntity id="B65" type="ICD10"></TargetEntity><TargetEntity id="10039603" type="MEDDRA"></TargetEntity><TargetEntity id="D012552" type="MeSH"></TargetEntity><TargetEntity id="1247" type="ORPHANET"></TargetEntity><TargetEntity id="-1643265988" type="omicsDisease"></TargetEntity><TargetEntity id="1752" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="936" type="ciIndication"><TargetEntity id="C46" type="ICD10"></TargetEntity><TargetEntity id="10023284" type="MEDDRA"></TargetEntity><TargetEntity id="D012514" type="MeSH"></TargetEntity><TargetEntity id="33276" type="ORPHANET"></TargetEntity><TargetEntity id="-1736755330" type="omicsDisease"></TargetEntity><TargetEntity id="682" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity></SourceEntity><SourceEntity id="2638" type="Action"><TargetEntity id="4959" type="Mechanism">Drugs Targeting Parasite Proteins</TargetEntity><TargetEntity id="4622" type="Mechanism">Drugs Targeting Plasmodium falciparum Proteins</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="153">Hepatitis C virus infection</Indication><Indication id="158">HIV infection</Indication><Indication id="1754">Cutaneous T-cell lymphoma</Indication><Indication id="1766">Renal cell carcinoma</Indication><Indication id="197">Leishmania tropica infection</Indication><Indication id="205">Melanoma</Indication><Indication id="221">Mycobacterium tuberculosis infection</Indication><Indication id="268">Plasmodium infection</Indication><Indication id="298">Schistosomiasis</Indication><Indication id="651">Cancer</Indication><Indication id="936">Kaposis sarcoma</Indication></IndicationsSecondary><ActionsPrimary><Action id="51207">Interleukin 12 ligand</Action></ActionsPrimary><ActionsSecondary><Action id="62253">Anticancer hormone</Action><Action id="991">Antiviral</Action><Action id="2638">Antiparasitic</Action><Action id="393">Immunostimulant</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="85">Protein recombinant</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra><Ephmra><Code>L3</Code><Name>IMMUNOSTIMULATING AGENTS</Name></Ephmra><Ephmra><Code>P</Code><Name>PARASITOLOGY</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-22T04:39:10.000Z</LastModificationDate><ChangeDateLast>2016-09-14T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="20511" linkType="Company"&gt;Wyeth BioPharma&lt;/ulink&gt; (formerly Genetics Institute), in collaboration with &lt;ulink linkID="14112" linkType="Company"&gt;Wyeth&lt;/ulink&gt;-Ayerst, was developing &lt;ulink linkID="6934" linkType="Drug"&gt;edodekin alfa&lt;/ulink&gt; (IL-12), for the potential treatment of cancer and viral infection including HIV infection. It had reached phase II trials by 1994 [&lt;ulink linkID="213946" linkType="reference"&gt;213946&lt;/ulink&gt;], [&lt;ulink linkID="174296" linkType="reference"&gt;174296&lt;/ulink&gt;], and these trials were ongoing in November 2001 [&lt;ulink linkID="408940" linkType="reference"&gt;408940&lt;/ulink&gt;], [&lt;ulink linkID="428972" linkType="reference"&gt;428972&lt;/ulink&gt;]. Phase I/II trials were initiated in Japan in 1998 for renal carcinoma and melanoma [&lt;ulink linkID="295049" linkType="reference"&gt;295049&lt;/ulink&gt;]. However, in June 2003, &lt;ulink linkID="14112" linkType="Company"&gt;Wyeth&lt;/ulink&gt; confirmed that development of the product had been discontinued [&lt;ulink linkID="494880" linkType="reference"&gt;494880&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt; &lt;ulink linkID="6934" linkType="Drug"&gt;Edodekin alfa&lt;/ulink&gt; was being developed by Yamanouchi in Japan under license from Genetics Institute [&lt;ulink linkID="191223" linkType="reference"&gt;191223&lt;/ulink&gt;]. Phase II trials conducted by Yamanouchi were underway in 1997 [&lt;ulink linkID="295049" linkType="reference"&gt;295049&lt;/ulink&gt;], [&lt;ulink linkID="270568" linkType="reference"&gt;270568&lt;/ulink&gt;]; however, no development has been reported by Yamanouchi since 1998.&lt;/para&gt;&lt;para&gt;In June 1995, phase II trials of &lt;ulink linkID="6934" linkType="Drug"&gt;edodekin alfa&lt;/ulink&gt;, conducted in 17 patients with advanced kidney cancer, were suspended after one patient died and ten others required hospitalization [&lt;ulink linkID="178867" linkType="reference"&gt;178867&lt;/ulink&gt;]. The adverse events have been shown to be due to an unexpected relationship between dosing and timing of dose administration and the FDA accepted a revised clinical protocol. Similarly, a phase I/II study of &lt;ulink linkID="6934" linkType="Drug"&gt;edodekin alfa&lt;/ulink&gt; in HIV, originally planned for the second half of 1995, was postponed until the adverse events were fully investigated [&lt;ulink linkID="179115" linkType="reference"&gt;179115&lt;/ulink&gt;]. Phase II safety trials for cancer and HIV infection were later resumed. The resumed trial for cancer was completed in late 1996 and the HIV phase I/II trial was expected to be finished in the first half of 1997 [&lt;ulink linkID="230848" linkType="reference"&gt;230848&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In May 2000, results from a phase II trial in patients with cutaneous T-cell lymphoma (CTCL) were presented at the 36th ASCO meeting in New Orleans, LA. This open-label, single agent study was initiated in August 1998 with a total of 23 previously treated patients. &lt;ulink linkID="6934" linkType="Drug"&gt;Edodekin alfa&lt;/ulink&gt; was administered at 100 ng/kg sc twice weekly for 2 weeks, with doses subsequently being raised to 300 ng/kg for the remainder of the 24-week dosing period. A partial response was observed in 43% of patients. Study treatment in a number of patients was discontinued early due to disease progression (n=5), adverse events (n=3), or other reasons (n=3). One patient died due to an autoimmune hemolytic anemia which was possibly related to study treatment [&lt;ulink linkID="368070" linkType="reference"&gt;368070&lt;/ulink&gt;]. A phase I and pharmacokinetic study, also presented at the 36th ASCO meeting, concluded that the recommended dose for phase II &lt;ulink linkID="6934" linkType="Drug"&gt;edodekin alfa&lt;/ulink&gt; trials in patients with advanced malignancies should be 300 ng/kg subcutaneously 3 times per week for 2 weeks followed by a 1-week rest, with this 3-week cycle being repeated as required [&lt;ulink linkID="369911" linkType="reference"&gt;369911&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2000, trial results were presented at the 56th AAAAI meeting in San Diego, CA. When administered in increasing doses edodekin reduced both blood and sputum eosinophilia, but did not affect the early and late bronchoconstriction [&lt;ulink linkID="360086" linkType="reference"&gt;360086&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2002, results from a phase I trial of twice-weekly iv &lt;ulink linkID="6934" linkType="Drug"&gt;edodekin alfa&lt;/ulink&gt; with low dose IL-2 was presented at the 38th ASCO annual meeting in Orlando, FL. The study enrolled 16 patients with advanced malignancies. The study showed that the modulation of &lt;ulink linkID="6934" linkType="Drug"&gt;edodekin alfa&lt;/ulink&gt;-induced immune activation by IL-2 was associated with tumor responses [&lt;ulink linkID="451017" linkType="reference"&gt;451017&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;By October 2001, recombinant human &lt;ulink linkID="6934" linkType="Drug"&gt;edodekin alfa&lt;/ulink&gt; had been shown to suppress hepatitis C RNA in a randomized, placebo-controlled, double-blind study of 24 chronic hepatitis C patients who previously failed treatment with interferon-alpha. It was safe and well-tolerated, with adverse events being arthralgias, myalgias, headache, fatigue, malaise, fever, oral mucositis, oral ulcer, depression, and mild alopecia. Withdrawal of treatment was associated with relapse [&lt;ulink linkID="494461" linkType="reference"&gt;494461&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By 1998, a phase I pharmacokinetic study in patients with renal cell cancer had been completed. The main adverse events seen were fever, flu-like symptoms, leukopenia and granulocytopenia [&lt;ulink linkID="273402" linkType="reference"&gt;273402&lt;/ulink&gt;], [&lt;ulink linkID="284166" linkType="reference"&gt;284166&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase I safety studies in more than 80 HIV and cancer patients showed only mild and reversible side effects. The company used a different dosing schedule in the phase II trials compared with phase I: phase I patients received a single injection and then a multiple dosing schedule while phase II patients began on a multiple dosing schedule. The change in dosing schedule may have had an impact.&lt;/para&gt;&lt;para&gt;In a phase I trial in patients with advanced malignancy, each received escalating iv doses of &lt;ulink linkID="6934" linkType="Drug"&gt;edodekin alfa&lt;/ulink&gt; (3 to 1000 ng/kg). The maximum tolerated dose was established as 500 ng/kg and the dose level was well tolerated. The elimination half-life was between 5 to 10 h. Biological effects included dose-dependent increases in  with some attenuation with successive cycles and dose-independent increases in serum . There was one transient complete response (melanoma) and one partial response (renal carcinoma) [&lt;ulink linkID="208781" linkType="reference"&gt;208781&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;During phase I trials in Japan, 12 patients were being administered &lt;ulink linkID="6934" linkType="Drug"&gt;edodekin alfa&lt;/ulink&gt; concentrations ranging from 100 ng/kg/day to 300 ng/kg/day. The patients had various types of progressive cancers. These studies were ongoing [&lt;ulink linkID="273593" linkType="reference"&gt;273593&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By year end 1995, the Genetics Institute and &lt;ulink linkID="14112" linkType="Company"&gt;Wyeth&lt;/ulink&gt;-Ayerst had formed a joint venture to commercialize &lt;ulink linkID="6934" linkType="Drug"&gt;edodekin alfa&lt;/ulink&gt; everywhere except Japan [&lt;ulink linkID="213946" linkType="reference"&gt;213946&lt;/ulink&gt;]. Yamanouchi was to commercialize the drug in Japan [&lt;ulink linkID="191223" linkType="reference"&gt;191223&lt;/ulink&gt;]; however, no development has been reported by Yamanouchi since 1998 [&lt;ulink linkID="295049" linkType="reference"&gt;295049&lt;/ulink&gt;], [&lt;ulink linkID="270568" linkType="reference"&gt;270568&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By 1994, Roche and the Genetics Institute had entered into a joint preclinical development agreement with the possibility of a further agreement for joint clinical development. Under the agreement, &lt;ulink linkID="26178" linkType="Company"&gt;F Hoffmann-La Roche Ltd&lt;/ulink&gt; was to be in charge of European development and &lt;ulink linkID="19461" linkType="Company"&gt;Hoffmann-La Roche Inc&lt;/ulink&gt; of development in the US [&lt;ulink linkID="156201" linkType="reference"&gt;156201&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;US-06423308 was assigned to &lt;ulink linkID="14112" linkType="Company"&gt;Wyeth&lt;/ulink&gt; in July 2002, claiming methods of using IL-12 to treat Kaposi's sarcoma (KS), particularly AIDS-associated KS.&lt;/para&gt;&lt;para&gt;ABN &lt;ulink linkID="14110" linkType="Company"&gt;AMRO&lt;/ulink&gt; predicted annual sales of SFr 20 million in 2000, rising to SFr 70 million in 2002 [&lt;ulink linkID="328676" linkType="reference"&gt;328676&lt;/ulink&gt;]. In February 1999, Lehman Brothers predicted the first major product launch to be in 2004, with sales peaking in 2009 [&lt;ulink linkID="319225" linkType="reference"&gt;319225&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;As of May 2003, there were insufficient data for an updated evaluation of this drug.&lt;/para&gt;&lt;para&gt;Dr PMS Chauhan, Medicinal Chemistry Division, &lt;ulink linkType="Company" linkID="15350"&gt;Central Drug Research Institute&lt;/ulink&gt;, Lucknow, India&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;10 April 1997&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Interleukin-12 (IL-12) was discovered in 1988, independently, by Roche, Genetics Institute and The Wistar Institute, who all have a cross-licensed right to the product. Genetics Institute named this compound, natural killer cell stimulatory factor (NKSF) [&lt;ulink linkType="reference" linkID="160965"&gt;160965&lt;/ulink&gt;], whilst Roche named it cytokine lymphocyte maturation factor (CLMF).  It became evident however, that the isolated compounds were the same, IL-12. Hoffman-La Roche disclosed the protein in its associated patent, EP-00433827.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;IL-12 was isolated from a human B-lymphoblastoid cell-line, which was induced to secrete lymphokines by culture with phorbol ester and calcium ionophore [&lt;ulink linkType="reference" linkID="96542"&gt;96542&lt;/ulink&gt;]. Analysis of the purified protein by sodium dodecyl sulfate/polyacrylamide gel electrophoresis, demonstrated that it is a 75 kDa heterodimer, composed of disulfide-bonded 40 kDa and 35 kDa subunits [&lt;ulink linkType="reference" linkID="96542"&gt;96542&lt;/ulink&gt;]. &lt;br/&gt; &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;In murine adenocarcinoma and sarcoma in vivo models, a prolonged survival and complete tumor regression was observed [&lt;ulink linkType="reference" linkID="161149"&gt;161149&lt;/ulink&gt;], indicating the antitumor activity of IL-12. In mice inoculated sc with BL-6 melanoma cells, IL-12 delayed the emergence of tumors [&lt;ulink linkType="reference" linkID="160721"&gt;160721&lt;/ulink&gt;]. Studies using  sensitized animals, including primates, have shown that the administration of IL-12, either systemically or locally, could inhibit a number of respiratory effects, such as eosinophil accumulation and edema airway hyper-responsiveness associated with allergen challenge [&lt;ulink linkType="reference" linkID="228805"&gt;228805&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In vitro and in vivo studies show that IL-12 exerts an immunostimulatory effect. The natural killer activity of IL-12 was demonstrated by in vitro studies in peripheral blood mononuclear cells (PBMC) obtained from patients with malignant diseases.  IL-12 restored the defective NK activity of PBMC and enhanced their cytolytic function [&lt;ulink linkType="reference" linkID="160726"&gt;160726&lt;/ulink&gt;].  Cynomolgus monkeys, on treatment with IL-12 at a dose of 1 microgram/kg/day, iv or sc, for five days, showed a transient decrease in WBC count compared to control, a reversible decrease mainly in lymphocytes and monocytes, and reversible thrombocytopenia and anemia [&lt;ulink linkType="reference" linkID="169366"&gt;169366&lt;/ulink&gt;]. Administration of IL-12 in humans has shown a dose-dependent increase in interferon-gamma and a dose-independent increase in serum neopterin [&lt;ulink linkType="reference" linkID="208781"&gt;208781&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;Studies on laboratory animals show that IL-12 has both adjuvant and prophylactic activities. Its administration is useful in the induction of protective immunity to malarial infection [&lt;ulink linkType="reference" linkID="235998"&gt;235998&lt;/ulink&gt;].  Rhesus monkeys were protected from challenge by malaria, when injected with 10 microgram/kg sc rh IL-12 [&lt;ulink linkType="reference" linkID="231862"&gt;231862&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="235992"&gt;235992&lt;/ulink&gt;].  The adjuvant activity of IL-12 was shown in BALB/c mice which were infected with Leishmania. Mice injected with leishmanial antigens and IL-12 were found to be resistant to further leishmanial infection [&lt;ulink linkType="reference" linkID="160720"&gt;160720&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;In humans, the maximum tolerated dose is 500 ng/kg [&lt;ulink linkType="reference" linkID="208781"&gt;208781&lt;/ulink&gt;] and the elimination half-life is 5 to 10 h [&lt;ulink linkType="reference" linkID="208781"&gt;208781&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;Toxicity studies in animals have not been reported in the literature.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I &lt;/subtitle&gt;In a phase I trial in patients with advanced malignancy, there was one transient, complete response (melanoma) and one partial response (renal carcinoma) [&lt;ulink linkType="reference" linkID="208781"&gt;208781&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II &lt;/subtitle&gt;Phase II trials of IL-12 in 17 patients with advanced kidney cancer were suspended after one patient died and ten others required hospitalization [&lt;ulink linkType="reference" linkID="178867"&gt;178867&lt;/ulink&gt;]. The adverse events were due to an unexpected relationship between the dose and time of administration. &lt;ulink linkType="Company" linkID="28926"&gt;The FDA&lt;/ulink&gt; accepted a revised clinical protocol. The resumed trial in cancer patients was completed in late 1996, and the  HIV phase I/II trial is expected to be completed in the first half of 1997 [&lt;ulink linkType="reference" linkID="230848"&gt;230848&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;Animal studies have demonstrated the strong prophylactic and immunostimulatory effect of IL-12.  IL-12 restores defective NK activity of PBMC and enhances PBMC proliferation from HIV-positive donors. IL-12 may have potential for the treatment of a variety of infections, including hepatitis, Leishmania tropica, tuberculosis, Plasmodium and schistosomiasis [&lt;ulink linkType="reference" linkID="179685"&gt;179685&lt;/ulink&gt;]. Genetics Institute and &lt;ulink linkType="Company" linkID="14112"&gt;Wyeth&lt;/ulink&gt;-Ayerst have formed a joint venture to commercialize IL-12 world-wide, excluding Japan, where Genetics Institute and Yamanouchi will market the drug.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1754">Cutaneous T-cell lymphoma</Indication><StatusDate>2003-06-27T00:00:00.000Z</StatusDate><Source id="494880" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14199">Wyeth Pharmaceuticals</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2003-06-27T00:00:00.000Z</StatusDate><Source id="494880" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19461">Hoffmann-La Roche Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2003-06-27T00:00:00.000Z</StatusDate><Source id="494880" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="268">Plasmodium infection</Indication><StatusDate>2003-06-27T00:00:00.000Z</StatusDate><Source id="494880" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="298">Schistosomiasis</Indication><StatusDate>2003-06-27T00:00:00.000Z</StatusDate><Source id="494880" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate>2003-06-27T00:00:00.000Z</StatusDate><Source id="494880" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14199">Wyeth Pharmaceuticals</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="936">Kaposis sarcoma</Indication><StatusDate>2003-06-27T00:00:00.000Z</StatusDate><Source id="494880" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1766">Renal cell carcinoma</Indication><StatusDate>2003-06-27T00:00:00.000Z</StatusDate><Source id="494880" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19461">Hoffmann-La Roche Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1766">Renal cell carcinoma</Indication><StatusDate>2003-06-27T00:00:00.000Z</StatusDate><Source id="494880" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="197">Leishmania tropica infection</Indication><StatusDate>2003-06-27T00:00:00.000Z</StatusDate><Source id="494880" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14199">Wyeth Pharmaceuticals</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate>2003-06-27T00:00:00.000Z</StatusDate><Source id="494880" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>2003-06-27T00:00:00.000Z</StatusDate><Source id="494880" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2003-06-27T00:00:00.000Z</StatusDate><Source id="494880" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate>2003-05-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate>2003-05-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1766">Renal cell carcinoma</Indication><StatusDate>2003-05-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19447">Nippon Roche KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><Source id="273593" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14199">Wyeth Pharmaceuticals</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="936">Kaposis sarcoma</Indication><StatusDate>1995-11-30T00:00:00.000Z</StatusDate><Source id="494472" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14199">Wyeth Pharmaceuticals</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><Source id="213946" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14199">Wyeth Pharmaceuticals</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><Source id="213946" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate>1998-08-06T00:00:00.000Z</StatusDate><Source id="295049" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1766">Renal cell carcinoma</Indication><StatusDate>1998-08-06T00:00:00.000Z</StatusDate><Source id="295049" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="158">HIV infection</Indication><Source id="191223" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2001-10-30T00:00:00.000Z</StatusDate><Source id="494461" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1754">Cutaneous T-cell lymphoma</Indication><StatusDate>2000-06-01T00:00:00.000Z</StatusDate><Source id="368070" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="298">Schistosomiasis</Indication><Source id="179685" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><Source id="179685" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="197">Leishmania tropica infection</Indication><Source id="179685" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="268">Plasmodium infection</Indication><Source id="179685" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>1996-10-03T00:00:00.000Z</StatusDate><Source id="220847" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1766">Renal cell carcinoma</Indication><Source id="174296" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20511">Wyeth BioPharma</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><Source id="174296" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19461">Hoffmann-La Roche Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>1994-01-01T00:00:00.000Z</StatusDate><Source id="179115" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19461">Hoffmann-La Roche Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1766">Renal cell carcinoma</Indication><StatusDate>1994-01-01T00:00:00.000Z</StatusDate><Source id="179329" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20511">Wyeth BioPharma</OwnerCompany><Country id="US">US</Country><Indication id="1766">Renal cell carcinoma</Indication><AwardedIndication>Treatment of renal cell carcinoma.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1997-10-20T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-09263"><Name>Interleukin 12 ligand</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>2</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>2</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="113154" title="Wyeth-Ayerst and Genetics Institute to develop IL-12 product"/><Deal id="120919" title="Yamanouchi Pharmaceutical to market Wyeth BioPharma's edodekin alfa in Japan"/><Deal id="120920" title="Roche and Genetics Institue to research and develop edodekin alfa"/></Deals><PatentFamilies><PatentFamily id="1288626" number="US-20030077818" title="Compositions and methods for targeting interleukin-12 to malignant endothelium"/><PatentFamily id="1325244" number="US-20090053171" title="Treatment of cellular proliferative disorders"/><PatentFamily id="1437644" number="WO-2005023328" title="Methods for intradermal delivery of therapeutics agents"/><PatentFamily id="1622097" number="WO-2006119897" title="Conjugate for targeting of drug"/><PatentFamily id="1807113" number="WO-2004089426" title="Radiolabeled cytokines and uses thereof as scintigraphic tracers for the imaging of chronic lymphocyte-mediated inflammations"/><PatentFamily id="1878998" number="WO-00197841" title="QS-21 and IL-12 as an adjuvant combination"/><PatentFamily id="1880862" number="WO-2005007093" title="Uses of IL-12 in hematopoiesis"/><PatentFamily id="1921980" number="WO-2011050286" title="Methods and compositions for enhancing polypeptide production"/><PatentFamily id="1939731" number="WO-09005147" title="Natural Killer Stimulatory Factor"/><PatentFamily id="2646514" number="WO-2013181566" title="Polysaccharide-based hydrogels and hybrid hydrogels and precursors thereof, methods of making same, and uses thereof"/><PatentFamily id="316923" number="WO-09624369" title="Formulations for IL-12."/><PatentFamily id="320603" number="WO-00015249" title="Treatment of Kaposi's sarcoma with IL-12"/><PatentFamily id="332201" number="WO-2008085557" title="Alphavirus replicon particles as immunological adjuvants."/><PatentFamily id="51597" number="WO-09601272" title="Helicobacter proteins and vaccines."/><PatentFamily id="541486" number="WO-09519786" title="Use Of Interleukin-12 To Prevent Graft Versus Host Disease"/><PatentFamily id="623234" number="WO-2005018665" title="Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens including &lt;i&gt;Plasmodium&lt;/i&gt; spp"/><PatentFamily id="697297" number="US-20050147689" title="Method for inhibiting the growth of gastrointestinal tract tumors"/><PatentFamily id="700063" number="WO-2007021822" title="Compositions and methods of preparation of liposomal microparticulate IL-12"/><PatentFamily id="846621" number="WO-2006101535" title="Inhibition of proteasome function to potentiate the proapoptotic and antitumor activity of cytokines"/><PatentFamily id="944881" number="US-06168923" title="Compositions and methods for use of il-12 as an adjuvant."/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>5</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="TherapyX Inc" id="1015169"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Arkansas State University" id="1034915"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BD Technologies" id="14596"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"/><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="McGill University" id="20617"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Pennsylvania" id="20658"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Southern California" id="20673"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wistar Institute of Anatomy &amp; Biology" id="20944"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Queensland Institute of Medical Research" id="21126"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rican Ltd" id="22855"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cornell University" id="24136"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universita degli Studi di Roma La Sapienza" id="24408"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="National Taiwan University" id="25104"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AlphaVax Inc" id="26417"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="State University of New York" id="26880"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ichor Medical Systems Inc" id="27705"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Philogen SpA" id="29032"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>